Skip to main content
Erschienen in: World Journal of Urology 2/2011

01.04.2011 | Original Article

Impact of oral anticoagulation on morbidity of transurethral resection of the prostate

verfasst von: Aurélien Descazeaud, Gregoire Robert, Souhil Lebdai, Alain Bougault, Abdel Rahmene Azzousi, Olivier Haillot, Marian Devonec, Marc Fourmarier, Christian Saussine, Nicolas Barry-Delongchamps, Alexandre de la Taille

Erschienen in: World Journal of Urology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Aim

To assess the impact of oral anticoagulation (OA) on morbidity of transurethral resection of the prostate (TURP). OA included warfarin and platelet aggregation inhibitors (PAI).

Patients and Method

Multicenter analysis of patients operated for symptomatic benign prostatic hyperplasia (BPH) by TURP. Patients under OA were compared to those with no OA.

Results

Out of 612 patients included in the analysis, 206 (33%) were on OA prior surgery (55 warfarin, 142 PAI, and 9 warfarin and PAI). No patient continued warfarin and clopidogrel during the operating period. Patients under OA were significantly older (75 vs. 71 yo, P < 0.001), had larger prostate volume (56 vs. 49 ml, P = 0.05), and had higher rate of bladder catheter prior surgery (26 vs. 17%, P = 0.02). At 3 months follow-up, patients in the OA group had a higher weight of resected tissue (24 vs. 21.7 g, P < 0.001), a longer duration of hospitalization (6.4 vs. 4.7 days P < 0.001), a higher rate of bladder clots (13 vs. 4.7%, P < 0.001), red cell transfusion (1.9 vs. 1.0%, P = 0.026), late hematuria (15.0 vs. 8.4%, P = 0.004), and thromboembolic events (2.4 vs. 0.7, P = 0.02). In multivariable analysis, OA status was the sole independent parameter associated with bladder clots (P = 0.004) and with late hematuria (P = 0.03).

Conclusion

OA had a significant and independent impact on TURP outcome in terms of bleeding complications. This data could be used for treatment decision and for patient’s information prior BPH surgery.
Literatur
1.
Zurück zum Zitat Reich O, Gratzke C, Bachmann A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10, 654 patients. J Urol 180:246–249PubMedCrossRef Reich O, Gratzke C, Bachmann A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10, 654 patients. J Urol 180:246–249PubMedCrossRef
2.
Zurück zum Zitat Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP (1999) Immediate and postoperative complications of transurethral prostatectomy in the 1990 s. J Urol 162:1307–1310PubMedCrossRef Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP (1999) Immediate and postoperative complications of transurethral prostatectomy in the 1990 s. J Urol 162:1307–1310PubMedCrossRef
3.
Zurück zum Zitat Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50:969–979PubMedCrossRef Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50:969–979PubMedCrossRef
4.
5.
Zurück zum Zitat Barmoshe S, Zlotta AR (2006) How do I treat and follow my TUNA patients. World J Urol 24:397–404PubMedCrossRef Barmoshe S, Zlotta AR (2006) How do I treat and follow my TUNA patients. World J Urol 24:397–404PubMedCrossRef
6.
Zurück zum Zitat Herrmann TR, Gross AJ, Schultheiss D, Kaufmann PM, Jonas U, Burchardt M (2006) Transurethral microwave thermotherapy for the treatment of BPH: still a challenger? World J Urol 24:389–396PubMedCrossRef Herrmann TR, Gross AJ, Schultheiss D, Kaufmann PM, Jonas U, Burchardt M (2006) Transurethral microwave thermotherapy for the treatment of BPH: still a challenger? World J Urol 24:389–396PubMedCrossRef
7.
Zurück zum Zitat Descazeaud A, Robert G, Azzousi AR et al (2009) Committee for lower urinary tract symptoms of the French Association of Urology. Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review. BJU Int 103:1162–1165PubMedCrossRef Descazeaud A, Robert G, Azzousi AR et al (2009) Committee for lower urinary tract symptoms of the French Association of Urology. Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review. BJU Int 103:1162–1165PubMedCrossRef
8.
Zurück zum Zitat Ruszat R, Wyler S, Forster T et al (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51:1031–1038PubMedCrossRef Ruszat R, Wyler S, Forster T et al (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51:1031–1038PubMedCrossRef
9.
Zurück zum Zitat Chakravarti A, Mawarfarinermott S (1998) Transurethral resection of the prostate in the anticoagulated patient. Br J Urol 81:520–522PubMed Chakravarti A, Mawarfarinermott S (1998) Transurethral resection of the prostate in the anticoagulated patient. Br J Urol 81:520–522PubMed
10.
Zurück zum Zitat Dotan ZA, Mor Y, Leibovitch I et al (2002) The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 168:610–613PubMedCrossRef Dotan ZA, Mor Y, Leibovitch I et al (2002) The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 168:610–613PubMedCrossRef
11.
Zurück zum Zitat Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64:623–625PubMedCrossRef Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64:623–625PubMedCrossRef
12.
Zurück zum Zitat Burger W, Chemnitius JM, Kneissl GD, Rücker G (2005) Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal vs. bleeding risks with its continuation—review and meta-analysis. J Intern Med 257:399–414PubMedCrossRef Burger W, Chemnitius JM, Kneissl GD, Rücker G (2005) Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal vs. bleeding risks with its continuation—review and meta-analysis. J Intern Med 257:399–414PubMedCrossRef
13.
Zurück zum Zitat Nielsen JD, Holm-Nielsen A, Jespersen J, Vinther CC, Settgast IW, Gram J (2000) The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy—a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol 34:194–198PubMedCrossRef Nielsen JD, Holm-Nielsen A, Jespersen J, Vinther CC, Settgast IW, Gram J (2000) The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy—a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol 34:194–198PubMedCrossRef
14.
Zurück zum Zitat Ruszat R, Wyler S, Forster T et al (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51:1031–1038PubMedCrossRef Ruszat R, Wyler S, Forster T et al (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51:1031–1038PubMedCrossRef
15.
Zurück zum Zitat Ehrlich Y, Yossepowitch O, Margel D, Lask D, Livne PM, Baniel J (2007) Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. J Urol 178:524–528PubMedCrossRef Ehrlich Y, Yossepowitch O, Margel D, Lask D, Livne PM, Baniel J (2007) Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. J Urol 178:524–528PubMedCrossRef
16.
Zurück zum Zitat Ten Cate H, Henny CP, ten Cate JW, Buller HR, Dabhoiwala NF (1987) Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients under going transurethral resection of the prostate. Thromb Haemost 57:92–96PubMed Ten Cate H, Henny CP, ten Cate JW, Buller HR, Dabhoiwala NF (1987) Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients under going transurethral resection of the prostate. Thromb Haemost 57:92–96PubMed
17.
Zurück zum Zitat Lund L, Moller Ernst Jnsen K, Torring N, Erik Niesen J (2005) Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol 39:160–162PubMedCrossRef Lund L, Moller Ernst Jnsen K, Torring N, Erik Niesen J (2005) Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol 39:160–162PubMedCrossRef
18.
Zurück zum Zitat Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A (2005) Effect of short term finasteride therapy on preoperative bleeding in patients who were candidates for transurethral resection of the prostate: a randomized controlled study. Prostate cancer Prostatic dis 8:215–218PubMedCrossRef Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A (2005) Effect of short term finasteride therapy on preoperative bleeding in patients who were candidates for transurethral resection of the prostate: a randomized controlled study. Prostate cancer Prostatic dis 8:215–218PubMedCrossRef
Metadaten
Titel
Impact of oral anticoagulation on morbidity of transurethral resection of the prostate
verfasst von
Aurélien Descazeaud
Gregoire Robert
Souhil Lebdai
Alain Bougault
Abdel Rahmene Azzousi
Olivier Haillot
Marian Devonec
Marc Fourmarier
Christian Saussine
Nicolas Barry-Delongchamps
Alexandre de la Taille
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 2/2011
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-010-0561-3

Weitere Artikel der Ausgabe 2/2011

World Journal of Urology 2/2011 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.